In particular, aromatase inhibitors (AIs), which lower circulating estrogens limiting their proliferative effect on breast cancer cells, are now the gold standard for the hormonal therapy of postmenopausal women with breast cancer [3]. The gene discussed is CYP19A1; the disease is breast carcinoma.